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Abstract
There is growing evidence for GABA and glutamate–glutamine dysfunction in the pathogenesis of mood and anxiety
disorders. It is important to study this pathology in the early phases of the illness in order to develop new approaches
to secondary prevention. New magnetic resonance spectroscopy (MRS) measures allow determining glutamine, the
principal metabolite of synaptic glutamate that is directly related to glutamate levels in the synaptic cleft, as well as
glutamate and GABA. In contrast to previous investigations, this study used community-based recruitment methods
and a combined categorical and dimensional approach to psychopathology. In the study protocol, neuroticism was
deﬁned as the primary outcome. Neuroticism shares a large proportion of its genetic variance with mood and anxiety
disorders. We examined young adult participants recruited from the general population in a cross-sectional study
using 3-T 1H-MRS with one voxel in the left dorsolateral prefrontal cortex (DLPFC). The total sample of N= 110 (61
females) included 18 individuals suffering from MDD and 19 individuals suffering from DSM-IV anxiety disorders. We
found that glutamine and glutamine-to-glutamate ratio were correlated with neuroticism in the whole sample (r=
0.263, p= 0.005, and n= 110; respectively, r= 0.252, p= 0.008, and n= 110), even when controlling for depression
and anxiety disorder diagnoses (for glutamine: beta= 0.220, p= 0.047, and n= 110). Glutamate and GABA were not
signiﬁcantly correlated with neuroticism (r= 0.087, p= 0.365, and n= 110; r=−0.044, p= 0.645, and n= 110). Lack of
self-conﬁdence and emotional instability were the clinical correlates of glutamate–glutamine dysfunction. In
conclusion, this study suggests that prefrontal glutamine is increased in early phases of mood and anxiety disorders.
Further understanding of glutamate–glutamine dysfunction in stress-related disorders may lead to new therapeutic
strategies to prevent and treat these disorders.
Introduction
Glutamate and GABA are the major excitatory and
inhibitory neurotransmitters in the human brain, respec-
tively. There is growing evidence that the central gluta-
mate system plays a major role in the pathogenesis of
mood and anxiety disorders1,2. The rapid and robust
antidepressant and anxiolytic effects of ketamine, which
acts on the glutamate system, suggest that dysfunction of
glutamate neurotransmission may be an early and primary
pathology of stress-related disorders3. Similarly, altera-
tions in GABAergic neurotransmission have been impli-
cated in depression and anxiety disorders, and positive
GABA modulators have also been reported to have
anxiolytic effects4.
Magnetic resonance spectroscopy (MRS) provides a
noninvasive tool for studying both the glutamate and
GABA systems in living humans. A series of MRS studies
demonstrated a highly consistent pattern of reduced
occipital GABA5,6 and reduced Glx (glutamate+glutamine)
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in the prefrontal cortex of acute, severe, and chronic
forms of major depressive disorder (MDD)7,8, but normal
Glx in milder and earlier stages of depression9–11 and in
panic disorder12. Increased Glx in the anterior cingulate
cortex (ACC) has also been found in healthy subjects with
high scores on the Spielberger trait anxiety scale13.
However, Glx and glutamate concentration are not indi-
cators of glutamate release but reﬂect
glutamate–glutamine cycling that is indistinguishable
from overall glutamate metabolism14.
More recent MRS studies have used methods to
decompose Glx into glutamate and glutamine con-
centrations. Glutamine levels are of particular interest
because they have been associated with glutamatergic
neurotransmitter activity in animals and humans7. In
addition, increased glutamine relative to glutamate levels
were found to be relevant for excitotoxicity15. Finally,
antidepressants appear to decrease glutamine levels16.
Taken together, glutamine levels may be relevant in the
vulnerability, pathogenesis, and treatment of mood and
anxiety disorders.
There is also preliminary evidence for increased gluta-
mine levels in MDD. Using MRS, Godlewska et al. found
increased glutamine levels in the putamen in unmedicated
individuals with MDD at an average age of 31 years17.
Abdallah et al. found increased prefrontal glutamine levels
in unmedicated MDD patients; in the patient group, they
identiﬁed a positive correlation between glutamine levels
and depressive symptoms18. These ﬁndings are in line
with a study that found increased glutamine concentra-
tion in the cerebrospinal ﬂuid (CSF) of subjects with
MDD19. There is also preliminary evidence that glutamine
is increased in anxiety disorders20, although other MRS
studies did not ﬁnd increased prefrontal glutamine in
MDD21–23.
However, many previous MRS studies were conducted
in chronically ill patients, where the effects of progression
and long-term medication use can present major con-
founds. To address these shortcomings, we used a
community-based sampling method in a relatively large
sample of the general population, focusing on young
adults, thereby reducing confounds associated with neu-
roprogression, long-term medication, and long-term
interactions with disease-related environmental factors.
We adopted a dimensional approach in addition to the
categorical approach to psychopathology that has been
used in previous neuroimaging studies. Neuroticism was
selected as the main outcome measure because while it
used to be considered as a general dimension of inter-
nalizing psychiatric conditions, more recent studies have
provided strong evidence that neuroticism is associated
with the etiology and pathogenesis of MDD24. Neuroti-
cism, mood, and anxiety disorders share many genetic risk
factors25,26, and levels of neuroticism strongly predict the
risk for both lifetime and new-onset MDD27. There are
some reports suggesting that the association between
neuroticism and depression is stronger in women than in
men28. In addition to neuroticism, we also examined trait
anxiety as a secondary end point as a dimensional con-
struct related to anxiety disorders.
We examined the link between neuroticism and gluta-
mate, glutamine, and GABA levels in the left DLPFC since
this region has been found to be relevant for the patho-
genesis of mood and anxiety disorders29. We hypothe-
sized that left DLPFC glutamate levels, reﬂecting reduced
glial cell density and size8, would not be related to neu-
roticism because such pathology appears to develop in
later stages of chronic psychiatric conditions. However,
we expected glutamine levels to be positively related to
neuroticism, reﬂecting increased glutamatergic neuro-
transmission as an early biomarker of MDD and other
stress-related internalizing psychiatric conditions. We
further expected GABA levels to be negatively correlated
with neuroticism, in keeping with the decreased GABA
levels previously reported in MDD8,30 and decreased
GABA levels as a response to acute stress31.
Subjects and methods
Subjects
Subjects were recruited using advertisements in local
newspapers as well as university blackboard webpages as
part of a large ongoing neuroimaging study. The recruit-
ment in the student environment provided us with a
sample of predominantly young adults. Subjects were
included into the study only after full explanation of the
goals of the study and the risks of the study procedures.
The study and the written consent were approved by the
local ethics committee (Kantonale Ethikkommission Zür-
ich). Individuals with severe psychiatric disorders such as
schizophrenia and acute eating disorders were excluded.
Of 192 subjects who underwent MRI scanning, ten were
excluded for poor spectral quality (manifested as a
Cramer–Rao lower bound (CRLB) of greater than 10% for
the N-acetyl-aspartate (NAA) ﬁt, see also32). Additional
two subjects were excluded because they had mild
abnormalities that could potentially inﬂuence the results
(one arachnoid cyst in the right posterior lateral ventricle
and one lipoma with dysplasia of the corpus callosum).
From these 180 datasets, only 114 had an estimated ﬁt for
glutamine that was lower than the quality criterion
(CRLB <= 30% for Gln in the edited spectra, see MRS
methods). In addition, four outliers in glutamine con-
centration, whose estimate was at least two standard
deviations higher than the mean, were excluded, resulting
in a sample size of 110. (The four outliers had been col-
lected in the beginning of the measurements, before a
change in the prescan settings, which improved the
spectral linewidth). In the whole sample, 81.7% did not
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smoke (less than one cigarette per day). Out of the
110 subjects, 18 were diagnosed with MDD, including 12
in partial or full remission. Two of the MDD cases were
on psychotropic medication (one on antidepressants and
one on thyroid hormone; one non-MDD subject was also
on thyroid hormone). Nineteen subjects had an DSM-IV
anxiety disorder (two had agoraphobia, ﬁve social phobia,
eight speciﬁc phobias, three panic disorder, two general-
ized anxiety disorder, three obsessive compulsive dis-
order, and ﬁve had posttraumatic stress disorder). Out of
these individuals with a psychiatric disorder, 11 suffered
from comorbid MDD/anxiety disorder. Table 1 displays
the clinical characteristics of the study sample categorized
by diagnosis. The sample size was larger than in most
previous MRS studies, suggesting enough power to detect
previously identiﬁed glutamate–glutamine abnormalities.
All psychiatric diagnoses were lifetime diagnoses.
Clinical assessments
Subjects underwent an extensive survey online, includ-
ing the neuroticism extraversion openness ﬁve-factor
inventory (NEO-FFI)33 and the trait section of the state
trait anxiety inventory (STAI)34. We used carefully vali-
dated German versions of these instruments35,36 and
double checked the items indicated in Table 2 regarding
the correct translation.
STAI and NEO-FFI were administered online some days
before the MRI session. On the day of the MRI session,
subjects ﬁlled out self-report questionnaires on acute
psychiatric symptoms: the state section of the STAI34,
Beck’s depression inventory (BDI)37, and Beck’s anxiety
inventory (BAI)38. Psychiatric diagnoses were made based
on the structured clinical interview for DSM-IV39.
MRI/MRS data collection
All participants were scanned with a 3.0 T GE Discovery
MR750, using an 8-channel receive-only head coil. The
scanning session included a localizer and a 3D T1-
weighted SPGR-sequence (consisting of 162 slices of
256 × 256 voxels, with a voxel resolution of 1 × 1 × 1mm;
TR= 11ms, TE= 5 ms, TI= 600ms, and ﬂip angle 8°),
used for localization of the MR spectra. As displayed in
Fig. 1, GABA-edited MR spectra were acquired from a
25 × 40 × 30mm voxel in the left frontal lobe using the
MEGA-PRESS method32,40, with TE= 69ms, TR=
Table 1 Clinical characteristics of the study sample
Healthy MDD only Anxiety only MDD/anx All
n 84 7 8 11 110
Female (%) 44 (52.3) 5 (71.4) 5 (62.5) 7 (63.6) 61 (55.5)
Age [y] (M, (SD)) 23.8 (3.9) 26.9 (8.1) 24.6 (2.3) 27.8 (2.8) 24.5 (4.3)
Education [y] (M, (SD)) 14.0 (2.7) 11.7 (2.5) 15.1 (3.1) 13.7 (3.6) 13.9 (2.9)
Neuroticism NeoFFI (M, (SD)) 15.3 (7.0) 24.1 (7.5) 17.1 (3.4) 31.9 (5.9) 17.6 (8.5)
STAI trait (M, (SD)) 32.6 (7.3) 43.6 (10.9) 33.0 (3.4) 56.3 (12.0) 35.7 (10.8)
BDI (M, (SD)) 2.27 (3.59) 8.50 (3.51) 1.38 (2.56) 16.00 (11.82) 3.94 (6.75)
BAI (M, (SD)) 3.13 (3.42) 7.71 (5.94) 3.88 (4.29) 13.00 (11.42) 4.48 (5.80)
This table displays demographics and psychiatric scales of the healthy individuals and those with mood and anxiety disorders. Anxiety disorder includes OCD and
PTSD as suggested by DSM-IV
Table 2 Associations between personality characteristics
and left DLPFC glutamine
Item label Pearson’s r Item text
Strongly correlating
STAIT03 0.295 I’m feeling like crying
STAIT12 0.267 I’m lacking self-conﬁdence
STAIT11 0.248 I tend to take things hard
NEO51 0.240 I’m often feeling helpless and wishing for
someone to solve my problems
NEO41 0.239 Too often I’m discouraged and want to give
up if something goes wrong
STAIT08 0.236 I believe that my problems are going to
outgrow me
Weakly correlating
NEO26 0.101 Sometimes I’m feeling completely worthless
STAIT06 −0.060 I’m feeling relaxed
NEO01 −0.041 I rarely feel lonesome or sad
STAIT15 0.040 I’m feeling downhearted
STAIT10 −0.029 I’m happy
STAIT01 0.010 I’m merry
This table displays associations between NEO-FFI neuroticism and STAI trait
items with left DLPFC glutamine concentrations, ordered by correlation
coefﬁcient
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2000 ms, 320 averages (160 pairs), and an eight-step phase
cycle. However, since the assessment of GABA with
MEGA-PRESS is confounded by the coediting of a mac-
romolecule, which contributes to the edited peak at 3ppm,
the GABA ﬁndings described represent GABA+ rather
than pure GABA values41.
MRI/MRS data analyses
All spectra were processed with LCModel version
6.3–1 H and visually inspected for the quality of the glu-
tamate/glutamine and GABA ﬁt (Fig. 2). Glutamate and
GABA levels with a CRLB of more than 20%, or glutamine
levels with a CRLB of more than 30% were excluded from
the analysis. All spectra also demonstrated a CRLB for
NAA of less than 10% and a CRLB for Glx of below 16%
for all participants (mean CRLB 5% and range 2%–13% for
the full group), in keeping with the quality criteria
recommended for separation of glutamate and glutamine
with MEGAPRESS42. In addition, the NAA linewidth was
below 8 Hz for 102/110 subjects in the Gln group (for the
remaining eight subjects, seven had a linewidth of 8–9 Hz
and one had a linewidth of 12 Hz).
T1-weighted images were segmented and warped into
standard MNI space using the ‘new segment’ procedure in
SPM12 for Matlab (http://www.ﬁl.ion.ucl.ac.uk/spm/
software/spm12). The segmented gray matter, white
matter, and CSF maps were written out in native space,
and the MRS concentrations were corrected for partial
volume CSF contamination, following the method
described in43.
Statistical analyses
We used Pearson’s correlation to test the main
hypothesis regarding the relationship between glutamine,
GABA, and neuroticism, In the event of a signiﬁcant
correlation emerging between the MRS measures and
neuroticism, additional posthoc correlations were derived
to test the strength of association between MRS levels and
the individual items of the NEO neuroticism and the
Fig. 1 MR images showing the position of the DLPFC voxel
Fig. 2 Representative spectrum from one participant, showing the
signal measured for each resonance frequency (represented by the
chemical shift in ppm). The spectral data are shown in black with the
LCModel ﬁt overlaid in red. The residuals of the ﬁt are shown above
the spectrum
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STAI trait anxiety questionnaires (Table 2), in order to
improve the clinical interpretation of the data. In order to
avoid confounds from differences in tissue composition
within the voxel, the correlations were performed both
with and without including the fraction of gray matter
within the MRS voxel as a covariate.
NEO-FFI and STAI trait anxiety were strongly corre-
lated (see below). In addition, glutamine, glutamate, and
GABA concentrations were intercorrelated. As a result,
testing for GABA, glutamate, and STAI trait anxiety was
not independent. Group comparisons of MRS measures
and diagnostic groups (MDD, anxiety disorders, and
controls) were performed with a Mann–Whitney U test.
Because we considered these analyses as exploratory, we
did not apply methods to correct for multiple compar-
isons. However, applying a Bonferroni correction factor of
6 to our results (accounting for six tests between gluta-
mine and NEO-FFI, STAI state anxiety, BAI, BDI, MDD
diagnosis, and anxiety disorder diagnosis) would result in
a corrected p-value of 0.05/6= 0.008.
Results
Glutamine, glutamate, and GABA in relation to anxious
personality and MDD
We found relationships between left prefrontal gluta-
mine concentration and both neuroticism (NEO-FFI, r=
0.263, p= 0.005, and n= 110, Fig. 3) and STAI trait (r=
0.201, p= 0.035, n= 110). Note that these two variables
were signiﬁcantly correlated (r= 0.840, p= 0.001, and
n= 110). There were no sex differences in these rela-
tionships (Fig. 3). There were no signiﬁcant correlations
between Glx (glutamate and glutamine) or GABA con-
centrations in the left prefrontal voxel and any depressive
or anxiety symptoms or personality traits, although glu-
tamate was positively correlated with GABA (r= 0.321,
p= 0.001, and n= 110) and negatively correlated with
glutamine (r=−0.304, p= 0.001, and n= 110). The sig-
niﬁcant association between neuroticism and glutamine
did not change if we used glutamine-to-glutamate ratio
instead of glutamine concentration (neuroticism NEO-
FFI, r= 0.252, p= 0.008, and n= 110), or if the gray
matter fraction within the voxel was included as a cov-
ariate (e.g., r= 0.265, p= 0.005, and n= 110, for the
partial correlation between glutamine and neuroticism,
corrected for the gray matter fraction). When controlling
for MDD diagnosis, DMS-IV anxiety disorder diagnosis,
smoking, age, and sex, the association between glutamine
concentration and neuroticism remained statistically sig-
niﬁcant (beta= 0.220, p= 0.047, and n= 110).
In the posthoc comparison between glutamine and
individual items of the NEO-FFI neuroticism and the
STAI trait anxiety questionnaires, one common element
of the most strongly correlating items seems to be per-
sonality traits such as lack of self-conﬁdence and
emotional instability, more than affective states such as
sadness and fear (Table 2).
To estimate the associations of both STAI trait anxiety
and neuroticism with glutamine concentrations, we con-
ducted a partial correlation analysis in which neuroticism
as a mediator variable was able to reduce the correlation
of STAI trait with glutamine concentration more strongly
(from r= 0.201, p= 0.035, and df= 108 to r=−0.038,
p= 0.695, and df= 107) than STAI trait was able to
reduce the correlation of neuroticism with glutamine
concentration (from r= 0.263, p= 0.005, and df= 108 to
r= 0.177, p= 0.065, and df= 107). State anxiety (STAI
state, BAI) did not correlate with left prefrontal glutamine
(r= 0.081, p= 0.405, and n= 108; r=−0.001, and p=
0.991, and n= 109) or any of the other concentrations
(Glutamate, Glx, GABA, NAA; all p > 0.132). There was
no correlation between glutamine and BDI scores (r=
0.135, p= 0.162, and n= 108) and BAI scores (r=
−0.001, p= 0.991, and n= 109).
Although our focus in this study was the dimensional
approach to psychopathology, we also analysed the data in
terms of DSM-IV diagnoses. As expected, the 18 subjects
with MDD (Table 1) with and without a current depres-
sive episode scored signiﬁcantly higher than controls (n=
92) on all psychiatric scales (p < 0.001). MDD had a ten-
dency toward higher glutamine concentrations in the left
DLPFC voxel (Mann–Whitney U test, p= 0.090). There
were no signiﬁcant differences in MRS measures between
Fig. 3 Relationship between glutamine concentration (corrected for
atrophy and water scaling) in a left prefrontal voxel and neuroticism
NEO-FFI for the male (blue) and female (green) subsample. Goodness
of ﬁt: r2= 0.069 (r= 0.263), F= 8.045, a= 10.277, b= 4.430; p= 0.005,
n= 110)
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partly/fully remitted MDD (N= 7) and acute MDD (N=
11). Removing the three medicated subjects did not
change these ﬁndings. The subjects with anxiety disorders
(n= 19) similarly scored higher in psychiatric scales than
the subjects without anxiety disorder (n= 91). They had
higher glutamine concentrations in a left prefrontal voxel
(Mann–Whitney U test, p= 0.025). Smoking and age did
not inﬂuence any of these associations.
Discussion
In this study, we demonstrated that glutamine con-
centrations in the left DLPFC were associated with neu-
roticism and trait anxiety. Individuals with anxiety
disorders had increased glutamine concentrations. While
glutamine was related to depressive and anxious person-
ality traits and anxiety disorders, it was not associated with
state anxiety or acute depressive symptoms. Individuals
with anxiety disorders had increased prefrontal GABA. In
contrast, GABA and glutamate concentrations were not
related to anxious personality and MDD in young adults.
We are not aware of previous studies on neuroticism
and glutamine. However, our main ﬁndings are in line
with recent MRS studies in MDD. Godlewska et al.17
examined 55 unmedicated depressed patients and 50
healthy controls, using MRS at 7 T. The mean age of their
samples was slightly higher than in our study (average of
31 years versus 25 years of age). In contrast to our study,
they did not examine the DLPFC, but examined the ACC,
the occipital cortex, and the putamen. Only in the puta-
men, they found increased glutamine concentrations in
the MDD sample. As in our study, they did not ﬁnd group
differences in glutamate concentrations in any of the three
voxels examined. Abdallah et al.18 included 16 MDD
subjects and 23 healthy controls in an MRS at 4 T study.
Their subjects were older than ours (with an average age
of 36 years), and they only examined the ACC, not the
DLFPC. Consistent with our study, they found increased
glutamine levels in subjects with MDD. In contrast to our
study, MDD was also associated with increased glutamate
levels. Levine et al.19 demonstrated a 17% increase in
glutamine concentrations in the CSF of 18 hospitalized
patients with acute unmedicated severe depression (mean
age 58 years) relative to 22 healthy controls. This ﬁnding
is consistent with our MRS results in a younger sample
with less severe MDD.
Consistently with our results, Jollant et al.44 found
increased glutamine concentrations in the right DLPFC in
25 unmedicated depressed patients, including 15 with a
history of suicidal behavior relative to 33 healthy controls.
However, this result did not survive Bonferroni’s correc-
tion or covariation with age. In 18 patients with
treatment-resistant depression, Baeken et al.21 found
decreased rather than increased glutamine levels in the
left DLPFC. In 14 medicated depressed children, Caetano
et al.22 found normal glutamine levels in the left DLPFC.
Taken together, previous MRS studies on DLPFC gluta-
mine concentration are heterogenous. They might suggest
that medication, disease stage, and age are relevant factors
that should be studied in larger samples.
A relatively recent meta-analysis on 17 reports found
reduced prefrontal Glx in MDD; the results were mainly
driven by glutamate10. Glx reduction was positively
associated with depression severity and age. This ﬁnding
is consistent with our ﬁnding of normal glutamate and
Glx levels in young MDD subjects in remitted or mild
depressive states. Our ﬁndings are also in agreement with
a recent meta-analysis including 49 studies and a total of
1180 MDD patients and 1066 controls on glutamatergic
metabolite levels that reported normal Glx levels in
unmedicated patients23. Further, our results are con-
sistent with recent large-scale genetic studies on neuro-
ticism that point to central glutamate-related genes to be
involved in neuroticism45.
The strengths of this study include the relatively large
total sample compared to previous MRS studies. We used
a dimensional approach to psychopathology that is con-
sistent with novel concepts of psychiatric diagnostics such
as NIMH’s Research Domain Criteria46. The study of
dimensional constructs related to mood and anxiety dis-
orders, such as anxious personality, and early phases of
MDD may add important information to investigations in
advanced stages of the illness.
The following limitations merit comment: Our MDD
and anxiety disorder samples were relatively small. We
used a 3 T scanner; higher ﬁeld strengths may have yiel-
ded better peak separation, particularly for glutamine
measurement. In addition, we used a voxel which contains
a higher proportion of white matter than other (e.g.,
anterior cingulate) frontal voxels, but which offers high
spectral quality and reliability, since high quality spectra
are a prerequisite for reliable separation of glutamine
from glutamate at 3 T. Two of our MDD subjects (one of
them with comorbid anxiety disorder) and 1 non-MDD
subject (without anxiety disorder) were on medication; we
did not exclude them to maintain the advantages of our
epidemiological sampling methods, making ﬁndings more
representative. In addition, no formal correction for
multiple comparisons was performed because the MRS
measures of interest (glutamate, glutamine, and GABA)
were intercorrelated and therefore not statistically inde-
pendent. In particular, since glutamate acts as a precursor
to GABA, which is cycled between astrocytes and neurons
via glutamine, glutamate in our sample was positively
correlated with GABA (r= 0.321, p= 0.001, and n= 110)
and negatively correlated with glutamine (r=−0.304,
p= 0.001, and n= 110).
Early in the pathogenesis of depression, glutamate-
related excitotoxicity may lead to reductions of gray
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matter and ﬁnally reduced brain metabolism in the
DLPFC47. In this context, our ﬁndings could be inter-
preted as reﬂecting increased glutamatergic activity as a
correlate of the early pathogenesis of MDD that is related
to underlying disease processes. The potential down-
regulation of the metabotropic glutamate receptor 5
(mGluR5)18 in the PFC as response to increased gluta-
mine concentrations is consistent with this interpretation.
The increased glutamine-to-glutamate ratio associated
with neuroticism and anxiety disorders may also reﬂect
early impairment of neuron–astrocyte integrity in the
development of mood and anxiety disorders48.
This study suggests that glutamatergic abnormality is
related to depression as well as to anxiety disorders. This
is consistent with our dimensional approach showing
association between increased prefrontal glutamine levels
and neuroticism. Increased glutamatergic activity may be
a promising target for pharmaceutical approaches to stop
neurotrophic processes, such as gray matter volume
reduction and glia cell pathology, in the early course of
mood and anxiety disorders. Finally, our ﬁndings might
encourage the testing of antidepressants such as phe-
nelzine that attenuate glutamate neurotransmission49, and
other glutamate-related drugs such as lamotrigine and
memantine50, in subjects with high prefrontal glutamine
levels in early phases of psychiatric disorders.
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